These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 35592355)
21. Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib. Tan AC; Loh TJ; Kwang XL; Tan GS; Lim KH; Tan DSW Lung Cancer (Auckl); 2021; 12():11-20. PubMed ID: 33776501 [TBL] [Abstract][Full Text] [Related]
22. Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation. Tanaka H; Taima K; Makiguchi T; Nakagawa J; Niioka T; Tasaka S Cancer Commun (Lond); 2021 Jan; 41(1):83-87. PubMed ID: 33387444 [TBL] [Abstract][Full Text] [Related]
23. Current and future treatment options for Hong L; Zhang J; Heymach JV; Le X Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443 [TBL] [Abstract][Full Text] [Related]
24. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Reungwetwattana T; Liang Y; Zhu V; Ou SI Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693 [TBL] [Abstract][Full Text] [Related]
25. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886 [TBL] [Abstract][Full Text] [Related]
27. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review. Tian J; Lin Z; Chen Y; Fu Y; Ding Z Front Oncol; 2022; 12():1006634. PubMed ID: 36387081 [TBL] [Abstract][Full Text] [Related]
28. Capmatinib in Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS; N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583 [TBL] [Abstract][Full Text] [Related]
30. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194 [TBL] [Abstract][Full Text] [Related]
31. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion. Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573 [TBL] [Abstract][Full Text] [Related]
32. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494 [TBL] [Abstract][Full Text] [Related]
33. Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Jørgensen JT; Mollerup J Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565287 [TBL] [Abstract][Full Text] [Related]
34. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Fujino T; Suda K; Mitsudomi T Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820 [TBL] [Abstract][Full Text] [Related]
36. Tepotinib in Non-Small-Cell Lung Cancer with Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185 [TBL] [Abstract][Full Text] [Related]
37. Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis. Kim TW; Lee KM; Lee SH Onco Targets Ther; 2022; 15():941-946. PubMed ID: 36072511 [TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer. Garon EB; Brodrick P Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808 [TBL] [Abstract][Full Text] [Related]
39. MYC amplification-conferred primary resistance to capmatinib in a Choi W; Jeong KC; Park SY; Kim S; Kang EH; Hwang M; Han JY Transl Lung Cancer Res; 2022 Sep; 11(9):1967-1972. PubMed ID: 36248327 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T Future Oncol; 2024 Apr; ():1-11. PubMed ID: 38629593 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]